0102030405
Caspofungin CAS No. 162808-62-0 Antibiotic Pharmaceutical Raw Material
02
introduce
introduce
Caspofungin is a semi-synthetic echinocandin antifungal and core pharmaceutical API, derived from the fermentation product of Glarea lozoyensis. It specifically inhibits fungal cell wall β(1,3)-D-glucan synthesis, exhibiting broad activity against Candida and Aspergillus species.
Widely used in clinical antifungal therapy and biomedical research, our products comply with strict international standards to ensure high purity, stable efficacy, and reliable supply.
02
Physical and chemical properties
Caspofungin exhibits key physical and chemical characteristics supporting its pharmaceutical and research applications, as follows:
- Boiling Point: 1408.1±65.0 °C
- Density: 1.36±0.1 g/cm³
- Flash Point: 805.4°C
- Solubility: Soluble in DMSO
- Boiling Point: 1408.1±65.0 °C
- Density: 1.36±0.1 g/cm³
- Flash Point: 805.4°C
- Solubility: Soluble in DMSO
1. Unique Mechanism of Action with Higher Safety
As an echinocandin antifungal, it exerts its effect by inhibiting the synthesis of 1,3-β-D-glucan in the fungal cell wall, a component absent in mammalian cells. Compared with antifungal drugs such as fluconazole and voriconazole, it has no targeting effect on normal human cells, causes less damage to the body, and has better medication safety.
2. Antibacterial Spectrum Adapts to Core Clinical Needs
It has good antibacterial activity against common clinically opportunistic pathogenic fungi, including Candida spp. and Aspergillus spp., and is also effective against the cyst form of Pneumocystis jirovecii. Compared with some antifungal drugs with a narrow antibacterial spectrum, it can address more types of invasive fungal infections.
3. Lower Resistance Risk and Applicable to Resistant/Intolerant Scenarios
Acquired resistance to it is extremely rare, with only a small number of resistant strains found in a few patients with treatment failure. It can effectively treat fluconazole-resistant or intolerant esophageal candidiasis, and is also indicated for invasive aspergillosis in patients who are intolerant to, resistant to, or unresponsive to voriconazole, filling the clinical gap after the failure of other antifungal treatments.
Its core application is antifungal treatment, applicable to various invasive infections caused by fungi, and also for the prevention and empirical treatment of fungal infections. The specific scenarios include:
1. Empirical antifungal treatment for high-risk patients with febrile neutropenia who have persistent fever after treatment with broad-spectrum antibiotics and require urgent antifungal intervention.
2. Treatment of invasive candidiasis, including candidemia, as well as abdominal abscess, peritonitis, thoracic infection and other diseases caused by Candida infection.
3. Treatment of esophageal candidiasis, especially for patients with refractory esophageal candidiasis or those who are intolerant to or resistant to other therapies.
4. Treatment of invasive aspergillosis in patients who are intolerant to, resistant to, or unresponsive to major antifungal drugs such as voriconazole.
5. Used as a preventive drug for invasive fungal infections in critically ill patients, and also as a targeted therapeutic drug after the occurrence of such infections.
2. Treatment of invasive candidiasis, including candidemia, as well as abdominal abscess, peritonitis, thoracic infection and other diseases caused by Candida infection.
3. Treatment of esophageal candidiasis, especially for patients with refractory esophageal candidiasis or those who are intolerant to or resistant to other therapies.
4. Treatment of invasive aspergillosis in patients who are intolerant to, resistant to, or unresponsive to major antifungal drugs such as voriconazole.
5. Used as a preventive drug for invasive fungal infections in critically ill patients, and also as a targeted therapeutic drug after the occurrence of such infections.
We implement strict full-process quality control, with each batch of Caspofungin undergoing rigorous testing of key indicators including purity, solubility, stability, protein binding rate, and microbial contamination to meet standards.
Equipped with a stable fermentation-semisynthesis supply chain, we ensure continuous large-scale supply. Our professional technical team provides tailored services, including reconstitution guidance, formulation optimization, and post-sales technical support for clinical and research applications.
Equipped with a stable fermentation-semisynthesis supply chain, we ensure continuous large-scale supply. Our professional technical team provides tailored services, including reconstitution guidance, formulation optimization, and post-sales technical support for clinical and research applications.
As the first approved echinocandin antifungal, Caspofungin remains a cornerstone in treating life-threatening invasive fungal infections, especially in immunocompromised patients. With its targeted mechanism, broad efficacy, exceptional quality, and reliable supply capacity, we are committed to providing high-quality Caspofungin API and professional services for global pharmaceutical companies, hospitals, and research institutions.
Choose our Caspofungin to meet your needs in clinical antifungal therapy, pharmaceutical formulation, and biomedical research. Contact us for more product details and cooperation support.
Choose our Caspofungin to meet your needs in clinical antifungal therapy, pharmaceutical formulation, and biomedical research. Contact us for more product details and cooperation support.